Neuronetics, Inc. (STIM)

Market Cap	240.07M
Revenue (ttm)	74.89M
Net Income (ttm)	-43.71M
Shares Out	63.68M
EPS (ttm)	-1.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,716,206
Open	4.000
Previous Close	4.000
Day's Range	3.575 - 3.945
52-Week Range	0.520 - 5.920
Beta	2.07
Analysts	Buy
Price Target	6.00 (+59.15%)
Earnings Date	Mar 4, 2025

About STIM

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 28, 2018
• Employees: 203
• Stock Exchange: NASDAQ
• Ticker Symbol: STIM
• Website: https://neurostar.com

Financial Performance

In 2024, Neuronetics's revenue was $74.89 million, an increase of 4.96% compared to the previous year's $71.35 million. Losses were -$43.20 million, 43.1% more than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for STIM stock is "Buy." The 12-month stock price forecast is $6.0, which is an increase of 59.15% from the latest price.

Price Target

$6.0

(59.15% upside)

Analyst Consensus: Buy